ATLANTA, GA, USA, October 24, 2023 /EINPresswire.com/ — The CMT Research Foundation, a non-profit centered solely on delivering remedies and cures for Charcot-Marie-Tooth illness (CMT)*, has invested in a challenge at Armatus Bio that may advance a novel miRNA gene Remedy candidate for CMT sort 1A designed to cut back PMP22 overexpression in Schwann cells, a recognized genetic driver of the illness. The remedy can be delivered by way of a single intrathecal injection, with the target of attaining clinically significant purposeful enhancements, enabling sufferers to retain actions of each day dwelling. If profitable, Armatus goals to provoke scientific trials of ARM-101 in early 2025.

“Armatus Bio is advancing a Gene Remedy candidate that has proven promising outcomes in early in vitro and animal mannequin research,” says Cleary Simpson, CEO of CMTRF. “So as to progress into human scientific trials, it is necessary to exhibit that the remedy can attain particular targets in animal fashions extra intently associated to people. Foundational research like these allow promising scientific ideas to transfer into human testing with elevated confidence in security and efficacy for a inhabitants in want.”

“We’re conducting a examine of the ARM-101 biodistribution to verify the Schwann cell focusing on success seen in mice and confirm applicable human doses in a mannequin that extra intently correlates to human biology,” says Rachel Salzman, DVM, Chief Govt Officer of Armatus Bio. “These foundational knowledge should not solely essential to advancing ARM-101 growth, but additionally present essential details about the power of precision therapies to goal applicable Points implicated in neuropathies.”

Armatus Bio, based mostly in Columbus Ohio, is an rising biotechnology firm making use of the rigor of superior bioengineering to the complicated problem of genetic drugs. Via dynamic collaborations with famend gene remedy consultants in Ohio, the corporate is constructing a pipeline of novel therapeutic candidates designed to overcome the constraints of at the moment’s approaches and propel the subsequent technology of genetic medicines.

CMT Research Foundation (CMTRF) is a patient-led, non-profit centered on delivering remedies and cures for CMT. The inspiration identifies vital obstacles or deficiencies impeding progress in direction of a treatment and seeks out collaborators to tackle these points. Up to now, CMTRF has funded 19 initiatives, of which 6 are accomplished. Of these 6 accomplished initiatives, 5 have scientific candidates. CMTRF’s mission to make investments in promising science with excessive potential of main to remedies and cures was confirmed efficient and ground-breaking when DTx Pharma with a CMTRF- backed program as its lead candidate was acquired by Novartis for $1 billion. Based by two sufferers who’re pushed to expedite drug supply to individuals who reside with CMT, the 501(c)(3) federal tax-exempt group is supported by private and company monetary presents.

*Charcot-Marie-Tooth encompasses a bunch of inherited, power peripheral neuropathies that outcome in nerve degradation. CMT sufferers endure from progressive muscle atrophy of legs and arms, inflicting strolling, operating and stability issues in addition to irregular functioning of fingers and ft. CMT impacts one in 2,500 individuals (about the identical prevalence as cystic fibrosis), together with 150,000 People and practically 3 million individuals worldwide. For the time being, there is no such thing as a remedy or treatment for CMT.

George H. Simpson
CMT Research Foundation
+1 203-521-0352
e mail us right here